Biopharmaceutical company PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq:JAZZ) jointly announced on Monday that a New Drug Application (NDA) has been accepted under the US Food and Drug Administration (FDA) Priority Review.
The companies are seeking accelerated approval for lurbinectedin to treat patients with Small Cell Lung Cancer (SCLC) who have progressed after prior platinum-containing therapy.
The US FDA has reportedly set a PDUFA target action date of 16 August 2020.
According to the companies, Lurbinectedin (PM1183) is a selective inhibitor of the oncogenic transcription programmes on which many tumours are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumour-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumour.
This US FDA submission is based on data from the partnership's Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.
A total of 105 patients from 39 centres were recruited in Europe and the US. The Phase II trial met its primary endpoint of the Objective Response Rate (ORR), concluded the companies.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval